Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression

Cancer Research

Volumn 60, Issue 9, 2000, Pages 2555-2561

  Murono, Shigeyuki ^a,c   Yoshizaki, Tomokazu ^c   Sato, Hiroshi ^c   Takeshita, Hajime ^c   Furukawa, Mitsuru ^c   Pagano, Joseph S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GELATINASE B; LATENT MEMBRANE PROTEIN 1;

ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; DRUG EFFECT; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; REPORTER GENE; TUMOR GROWTH;

ANIMALS; ASPIRIN; BLOTTING, WESTERN; CELL NUCLEUS; CHLORAMPHENICOL O-ACETYLTRANSFERASE; ENZYME INHIBITORS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NF-KAPPA B; PLASMIDS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SODIUM SALICYLATE; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

EID: 0034192392     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Liabakk, N. B., Talbot, I., Smith, R. A., Wilkinson, K., and Balkwill, F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res., 56: 190-196, 1996.
2. Parsons, S. L., Watson, S. A., Collins, H. M., Griffin, N. R., Clarke, P. A., and Steele, R. J. Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br. J. Cancer, 78: 1495-1502, 1998.
3. Weiss, L. M., Chen, Y. Y., Liu, X. F., and Shibata, D. Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. Am. J. Pathol., 139: 1259-1265, 1991.
4. Pallesen, G., Hamilton-Dutoit, S. J., Rowe, M., Lisse, I., Ralfkiaer, E., Sandvej, K., and Young, L. S. Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. J. Pathol., 165: 289-299, 1991.
5. Harabuchi, Y., Yamanaka, N., Kataura, A., Imai, S., Kinoshita, T., Mizuno, F., and Osato, T. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet, 335: 128-130, 1990.
6. Raab-Traub, N., Flynn, K., Pearson, G., Huang, A., Levine, P., Lanier, A., and Pagano, J. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int. J. Cancer, 39: 25-29, 1987.
7. Murono, S., Yoshizaki, T., Tanaka, S., Takeshita, H., Park, C. S., and Furukawa, M. Detection of Epstein-Barr virus in nasopharyngeal carcinoma by in situ hybridization and polymerase chain reaction. Laryngoscope, 107: 523-526, 1997.
8. Wang, D., Liebowitz, D., and Kieff, E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell, 43: 831-840, 1985.
9. Yoshizaki, T., Sato, H., Furukawa, M., and Pagano, J. S. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA, 95: 3621-3626, 1998.
10. Huen, D. S., Henderson, S. A., Croom-Carter, D., and Rowe, M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene, 10: 549-560, 1995.
11. Takeshita, H., Yoshizaki, T., Miller, W. E., Sato, H., Furukawa, M., Pagano, J. S., and Raab-Traub, N. Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. J. Virol., 73: 5548-5555, 1999.
12. Stancovski, I., and Baltimore, D. NF-κB activation: the IκB kinase revealed? Cell, 91: 299-302, 1997.
13. Verma, I. M. and Stevenson, J. IκB kinase: beginning, not the end. Proc. Natl. Acad. Sci. USA, 94: 11758-11760, 1997.
14. Kopp, E., and Ghosh, S. Inhibition of NF-κB by sodium salicylate and aspirin. Science (Washington DC), 265: 956-959, 1994.
15. Yin, M. J., Yamamoto, Y., and Gaynor, R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature (Lond.), 396: 77-80, 1998.
16. Huang, C., Ma, W. Y., Hanenberger, D., Cleary, M. P., Bowden, G. T., and Dong, Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J. Biol. Chem., 272: 26325-26331, 1997.
17. Sato, H., and Seiki, M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene, 8: 395-405, 1993.
18. Sato, H., Kita, M., and Seiki, M. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem., 268: 23460-23468, 1993.
19. Yoshizaki, T., Sato, H., Maruyama, Y., Murono, S., Furukawa, M., Park, C. S., and Seiki, M. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer (Phila.)., 79: 139-144, 1997.
20. Davenport, M. G., and Pagano, J. S. Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus Type I latency. J. Virol., 73: 3154-3161, 1999.
21. Kulwichit, W., Edwards, R. H., Davenport, E. M., Baskar, J. F., Godfrey, V., and Raab-Traub, N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA, 95: 11963-11968, 1998.
22. Yurochko, A. D., Hwang, E. S., Rasmussen, L., Keay, S., Pereira, L., and Huang, E. S. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-κB during infection. J. Virol., 71: 5051-5059, 1997.
23. Mercurio, F., Zhu, H., Murray, B. W., Shevchenko, A., Bennett, B. L., Li, J., Young, D. B., Barbosa, M., Mann, M., Manning, A., and Rao, A. IKK-1 and 1KK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science (Washington DC), 278: 860-866, 1997.
24. Kieser, A., Kilger, E., Gires, O., Ueffing, M., Kolch, W., and Hammerschmidt, W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J., 16: 6478-6485, 1997.
25. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
26. Dawson, C. W., Rickinson, A. B., and Young, L. S. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (Lond.), 344: 777-780, 1990.
27. Fahraeus, R., Rymo, L., Rhim, J. S., and Klein, G. Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (Lond.), 345: 447-449, 1990.
28. Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K., and Raah-Traub, N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med., 333: 693-698, 1995.
29. Hu, L. F., Chen, F., Zhen, Q. F., Zhang, Y. W., Luo, Y., Zheng, X., Winberg, G., Ernberg, I., and Klein, G. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur. J. Cancer, 5: 658-660, 1995.
30. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C., and Kieff, E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 80: 389-399, 1995.
31. Devergne, O., Hatzivassiliou, E., Izumi, K. M., Kaye, K. M., Kleijnen, M. F., Kieff, E., and Mosialos, G. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol. Cell Biol., 16: 7098-7108, 1996.
32. Izumi, K. M., and Kieff, E. D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc. Natl. Acad. Sci. USA, 94: 12592-12597, 1997.
33. Eliopoulos, A. G., Dawson, C. W., Mosialos, G., Floettmann, J. E., Rowe, M., Armitage, R. J., Dawson, J., Zapata, J. M., Kerr, D. J., Wakelam, M. J., Reed, J. C., Kieff, E., and Young, L. S. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene, 13: 2243-2254, 1996.
34. Sylla, B. S., Hung, S. C., Davidson, D. M., Hatzivassiliou, E., Malinin, N. L., Wallach, D., Gilmore, T. D., Kieff, E., and Mosialos, G. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ. Proc. Natl. Acad. Sci. USA, 95: 10106-10111, 1998.
35. Schreinemachers, D. M., and Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.
36. Schwenger, P., Bellosta, P., Victor, I., Basilico, C., Skolnik, E. Y., and Vilcek, J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA, 94: 2869-2873, 1997.
37. Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler, R., Pich, D., and Hammerschmidt, W. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J., 16: 6131-6140, 1997.
38. Bernhard, E. J., Gruber, S. B., and Muschel, R. J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA, 91: 4293-4297, 1994.
39. Hua, J., and Muschel, R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res., 56: 5279-5284, 1996.
40. Cha, H. J., Bae, S. K., Lee, H. Y., Lee, O. H., Sato, H., Seiki, M., Park, B. C., and Kim, K. W. Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res., 56: 2281-2284, 1996.
41. Stein, B., Baldwin, A. S., Jr., Ballard, D. W., Greene, W. C., Angel, P., and Herrlich, P. Cross-coupling of the NF-βB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J., 12: 3879-3891, 1993.
42. Li, J. J., Westergaard, C., Ghosh, P., and Colburn, N. H. Inhibitors of both nuclear factor-κB and activator protein-1 activation block the neoplastic transformation response. Cancer Res., 57: 3569-3576, 1997.
43. Uemura, K., Takao, S., and Aikou, T. In vitro determination of basement membrane invasion predicts liver metastases in human gastrointestinal carcinoma. Cancer Res., 58: 3727-3731, 1998.